Alto Neuroscience is a clinical-stage biopharmaceutical company developing personalized medicines for neuropsychiatric conditions such as major depressive disorder, bipolar depression, and schizophrenia. It uses brain-biology measures and biomarkers to match drug candidates to patients most likely to respond, aiming to replace trial-and-error prescribing. Pipeline programs include small-molecule candidates designed around core neural processes rather than one-size-fits-all psychiatric drugs.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -15.2 | — |
| Q2 2025 | 0 | — | -17.7 | — |
| Q3 2025 | 0 | — | -14.2 | — |
| Q4 2025 | 0 | — | -16.2 | — |
| Q1 2026 | 0 | — | -26.2 | — |
All markets — KeepWinning global stock screener
Other companies on NYSE: Empire State Realty Trust, Inc. (ESRT), Alexander's, Inc. (ALX), Borr Drilling Limited (BORR), Companhia Siderúrgica Nacional (SID), Lightspeed Commerce Inc. (LSPD), Navigator Holdings Ltd. (NVGS)